Patents Assigned to Inserm
  • CHIMERIC POLYPEPTIDE COMPRISING THE FRAGMENT B OF SHIGA TOXIN AND PEPTIDES OF THERAPEUTIC INTEREST
    Publication number: 20170015719
    Abstract: The invention pertains to methods for using chimeric polypeptides of the formula: B-X wherein B represents the B fragment of Shiga toxin or a functional equivalent thereof, and X represents one or more polypeptides of therapeutic significance. Compositions for therapeutic use comprising the polypeptide B-X are also included.
    Type: Application
    Filed: July 26, 2013
    Publication date: January 19, 2017
    Applicants: Inserm, Centre National de la Recherche Scientifique (CNRS), Institut Curie, Universite Pierre Et Marie Curie (Paris 6)
    Inventors: Bruno Goud, Ludger Johannes
  • Correlation of disease activity with clonal expansions of human papillomavirus 16-specific CD8+ T-cells in patients with severe erosive oral lichen planus
    Patent number: 9547006
    Abstract: A massive clonal expansion of activated CD8+ T-cells with increased frequency of HPV 16-specific CD8+ T-cells was discovered to be a characteristic of oral lichen planus (OLP), indicating a causal link between HPV infection and the dysimmune process. The invention relates to compositions and methods for the diagnosis and treatment of OLP patients.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: January 17, 2017
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DIDEROT—PARIS 7, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Marie-Lise Gougeon, Manuelle Viguier, Herve Bachelez, Nicolas Fazilleau
  • Method for activating a chemical reaction, solution that can be activated by said method and device for implementing said method
    Patent number: 9545375
    Abstract: The invention relates to a method which comprises emitting ultrasound into a liquid mixture containing first and second reagents in separate phases initially separated by a liquid precursor-gas barrier, the ultrasound having a high enough energy level to vaporize the precursor gas, such as to contact the reagents and thus to activate a chemical reaction therebetween.
    Type: Grant
    Filed: January 3, 2014
    Date of Patent: January 17, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, ECOLE SUPERIEURE DE PHYSIQUE ET CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Olivier Couture, Mickael Tanter, Patrick Tabeling, Janine Cossy, Mathias Fink
  • Diagnosis of hereditary spastic paraplegias (HSP) by detection of a mutation in the KIAA1840 gene or protein
    Patent number: 9546402
    Abstract: An ex vivo method of diagnosing or predicting an hereditary spastic paraplegias (HSP) in a subject is provided which comprises detecting a mutation in the KIAA1840 gene or protein (spatacsin), wherein that mutation is indicative of an hereditary spastic paraplegias (HSP).
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: January 17, 2017
    Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Hamid Azzedine, Alexis Brice, Giovanni Stevanin, Filippo Santorelli, Paola Denora
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEART FAILURE
    Publication number: 20170002358
    Abstract: The present invention relates to an inhibitor of NGAL gene expression or a NGAL antagonist for use in the prevention or the treatment of heart failure.
    Type: Application
    Filed: August 29, 2016
    Publication date: January 5, 2017
    Applicant: Institut National de la Sante et de la Recherche M edicale (INSERM)
    Inventors: Frédéric JAISSER, Nicolette FARMAN
  • USE OF A NEUROFILAMENT PEPTIDE FOR THE TREATMENT OF GLIOMA
    Publication number: 20170000846
    Abstract: The present invention provides a new drug to treat malignant glioma, which is the most prevalent type of primary tumor of the central nervous system (CNS). The present invention indeed shows that the isolated NFL-TBS40-63 peptide is highly specific for glioma cells, in which it triggers apoptosis. It is therefore presented here for use in a method for treating malignant glioma. The present invention further relates to the use of the NFL-TBS40-63 peptide for detecting specifically glioma cells either in vivo, or in vitro, or for addressing chemical compounds to said tumor cells.
    Type: Application
    Filed: August 5, 2016
    Publication date: January 5, 2017
    Applicants: UNIVERSITE D'ANGERS, INSTITU NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
    Inventors: Joel Eyer, Alan Peterson, Julien Balzeau, Raphael Berges
  • Detection of platelet-derived shed CD31
    Patent number: 9534036
    Abstract: The present invention relates to various soluble forms of CD31, including a novel form which is shed by activated platelets and released into the circulation. Methods for detecting said soluble forms of CD31 are disclosed, as are methods of specifically 1 detecting said platelet-derived shed CD31 and the use of such methods as a diagnostic tool.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 3, 2017
    Assignees: Insitut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Diderot—Paris 7, Universite Paris 13—Paris Nord, Assistance Publique—Hopitaux de Paris
    Inventors: Giuseppina Caligiuri, Antonino Nicoletti
  • METHOD FOR REJUVENATING CELLS
    Publication number: 20160376560
    Abstract: The invention relates to a method for reprogramming cells from aged donors or senescent cells to pluripotent cells that have lost marks of senescence. In particular, the invention relates to an ex vivo method for preparing induced pluripotent stein cells (iPSCs) from a target cell population comprising cells from aged donors or senescent cells, said method comprising the steps of culturing said target cell population under appropriate conditions for reprogramming said cells into iPSCs, wherein said appropriate conditions comprises increasing expression in said target cells, of at least the following reprogramming factors: Oct4, Klf4, Sox2, Myc, Lin28 and, optionally Nanog.
    Type: Application
    Filed: September 12, 2016
    Publication date: December 29, 2016
    Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE MONTPELLIER I, UNIVERSITE MONTPELLIER II
    Inventors: Alexandre PRIEUR, Ollivier MILHAVET, Jean-Marc LEMAITRE, Laure LAPASSET
  • Selective histamine H4 receptor antagonists for the treatment of vestibular disorders
    Patent number: 9526725
    Abstract: The invention relates to Histamine H4 receptor antagonists or inhibitors of Histamine H4 receptor gene expression for the treatment and/or the prevention of vestibular disorders.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: December 27, 2016
    Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Giles Desmadryl, Christian Chabbert
  • Recombinant strains
    Patent number: 9528086
    Abstract: A genetically attenuated Bordetella pertussis strain includes a mutated pertussis toxin (ptx) gene, and a heterologous ampG gene, and a hybrid protein including the N-terminal fragment of filamentous haemagglutinin (FHA) and a heterologous epitope or antigenic protein or protein fragment, different from FHA. The strain can be used in an attenuated vaccine for the treatment or prophylaxis of an infectious disease.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: December 27, 2016
    Assignees: UNIVERSITÉ DROIT ET SANTÉ LILLE II, INSERM, INSTITUT PASTEUR DE LILLE
    Inventors: Camille Locht, Nathalie Mielcarek, Hana Kammoun
  • Immunoadjuvant flagellin-based compounds and use thereof
    Patent number: 9527891
    Abstract: The present invention relates to novel peptide compounds derived from flagellin originating from Salmonella enterica that exhibit an in vivo immune adjuvant activity.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: December 27, 2016
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), INSTITUT PASTEUR DE LILLE
    Inventor: Jean-Claude Sirard
  • METHODS FOR DIAGNOSING AND TREATING MYHRE SYNDROME
    Publication number: 20160369348
    Abstract: The present invention relates to methods for diagnosing and treating Myhre Syndrome. The invention provides a method for diagnosing or predicting Myhre Syndrome, or a risk of Myhre Syndrome, in a subject, which method comprises detecting a mutation in SMAD4 gene, as compared to a control population, wherein the presence of said mutation is indicative of Myhre Syndrome or of a risk of Myhre Syndrome. The present invention also relates to an inhibitor of the SMAD4-mediated TG?/BMP signalling pathway for use in the treatment of Myhre Syndrome.
    Type: Application
    Filed: September 6, 2016
    Publication date: December 22, 2016
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Universite Paris Descartes - Paris V
    Inventors: Valerie Cormier-Daire, Carine Le Goff, Arnold Munnich
  • METHOD FOR PRODUCING INDUCED PLURIPOTENT CELLS
    Publication number: 20160369242
    Abstract: The invention relates to a method for producing induced pluripotent stem cells (iPS) by culturing somatic cells subjected to a cellular reprogramming method, characterised in that the somatic cells are cultured in the presence of netrin-1 or an analogue of netrin-1 at least at the beginning of the cellular reprogramming method.
    Type: Application
    Filed: January 13, 2015
    Publication date: December 22, 2016
    Applicants: CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD LYON 1, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M EDICALE (INSERM)
    Inventors: Fabrice LAVIAL, Patrick MEHLEN, Agnès BERNET
  • Diagnosis of hereditary spastic paraplegias (HSP) by identification of a mutation in the ZFYVE26 gene or protein
    Patent number: 9522933
    Abstract: The Invention relates to an ex vivo method of diagnosing or predicting a hereditary spastic paraplegias (HSP), in a subject, which method comprises detecting a mutation in the ZFYVE26 gene or protein (spastizin), wherein said mutation is indicative of a hereditary spastic paraplegias (HSP).
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: December 20, 2016
    Assignee: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)
    Inventors: Giovanni Stevanin, Sylvain Hanein, Amir Boukhris, Cyril Goizet, Elodie Martin, Alexis Brice
  • Method for preparing porous scaffold for tissue engineering, cell culture and cell delivery
    Patent number: 9522218
    Abstract: The present invention relates to a method for preparing a porous scaffold for tissue engineering. It is another object of the present invention to provide a porous scaffold obtainable by the method as above described, and its use for tissue engineering, cell culture and cell delivery. The method of the invention comprises the steps consisting of: a) preparing an alkaline aqueous solution comprising an amount of at least one polysaccharide, an amount of a cross-linking agent and an amount of a porogen agent b) transforming the solution into a hydrogel by placing said solution at a temperature from about 4° C. to about 80° C. for a sufficient time to allow the cross-linking of said amount of polysaccharide and c) submerging said hydrogel into an aqueous solution d) washing the porous scaffold obtained at step c).
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: December 20, 2016
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris 7—Denis Diderot
    Inventors: Catherine Le Visage, Didier Letourneur
  • Cryopreservation of cells, tissues and organs
    Patent number: 9521839
    Abstract: The present invention provides a method for cryoprotecting a biological specimen comprising the step of freezing said biological specimen in the presence of a hydrogel and in the absence of cryoprotectant.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: December 20, 2016
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DESCARTES (PARIS V), UNIVERSITE DE VERSAILLES—SAINT QUENTIN EN YVELINES
    Inventors: Anne Pelle Meddahi, Aicha Abed, Didier Letourneur, Anne Baudot
  • BIOACTIVE MODIFICATION OF POLY(VINYL ALCOHOL) WITH SURFACE TOPOGRAPHY AND BIOCHEMICAL CUES FOR VASCULAR GRAFT
    Publication number: 20160361462
    Abstract: Modifications of the biomaterial poly(vinyl alcohol) with surface topographical cues, attachment factors for its improved performance, and/or sustained release of vascular endothelial biochemical cue for application as a vascular graft scaffold is described. Furthermore, novel fabrication methods to pattern the poly(vinyl alcohol) hydrogel in planar film or tubular form with the topographies in the lumen are disclosed.
    Type: Application
    Filed: April 13, 2016
    Publication date: December 15, 2016
    Applicants: NATIONAL UNIVERSITY OF SINGAPORE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: King Fai Evelyn YIM, Catherine LE VISAGE, Marie Francene Arnobit CUTIONGCO, Ming Hao TAN, Seok Hong GOH
  • TREATMENT OF CARDIAC DISEASES WITH MODULATORS OF THE HIPPO PATHWAY
    Publication number: 20160361340
    Abstract: The present invention provides methods of treating and preventing cardiac hypertrophy and heart failure. Further provided are transgenic animals exhibiting altered expression of the atypical cadherin Fat4 and methods using said transgenic animals, or cells isolated therefrom, for the detection of compounds having therapeutic activity toward cardiac hypertrophy or regeneration. Embodiments of the present invention provide methods and composition for therapeutic intervention in cardiac hypertrophy or heart repair by modulating Fat4 and/or Amotl1 (angiomotin-like1). Treatment may include deleting Yap or administering verteporfm. Embodiments of the present invention define the molecular events linking Fat4 and Amotl1 to cardiac growth, and show that Fat4 is required to restrict cardiomyocyte hypertrophy and cardiomyocyte proliferation and that this is mediated by Amotl1.
    Type: Application
    Filed: February 11, 2015
    Publication date: December 15, 2016
    Applicants: Inetitut Pasteur, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Sigolene MEILHAC, Chiara RAGNI, Jean-Francois LE GARREC, Nicolas DIGUET
  • High intensity focused ultrasound device with a concave segment shaped transducer for eye treatment
    Patent number: 9517359
    Abstract: A device for treatment of an ocular pathology characterized in that it comprises at least one eye ring (1) wherein the proximal end of said eye ring (1) is suitable to be applied onto the globe and a generator (2,17) to generate ultrasound beam fixed on the distal end of the eye ring (1), the generator to generate ultrasound beam presenting a concave segment shape conformed along a single curvature corresponding to a single direction wherein the concavity is designed to be tuned towards the eyeglobe.
    Type: Grant
    Filed: August 18, 2009
    Date of Patent: December 13, 2016
    Assignees: EYE TECH CARE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Fabrizio Romano, Cyril Lafon, Jean-Yves Chapelon, Françoise Chavrier, Alain Birer, Laurent Farcy, Philippe Chapuis
  • FKBP52-Tau interaction as a novel therapeutical target for treating the neurological disorders involving Tau dysfunction
    Patent number: 9518995
    Abstract: Candidate compounds for use in neuro-protection and repair in neurological disorders involving Tau dysfunction (including Alzheimer's disease) are identified from a direct interaction between proteins FKBP52 and Tau. The method for screening a drug for the prevention and treatment of neurological disorders involving Tau dysfunction includes determining the ability of a candidate compound, to modulate binding between a Tau polypeptide and a FKBP52 polypeptide, and selecting positively the candidate compound that modulates binding.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: December 13, 2016
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Etienne Baulieu, Beatrice Chambraud